BRPI0720546A2 - Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto - Google Patents

Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto

Info

Publication number
BRPI0720546A2
BRPI0720546A2 BRPI0720546-5A BRPI0720546A BRPI0720546A2 BR PI0720546 A2 BRPI0720546 A2 BR PI0720546A2 BR PI0720546 A BRPI0720546 A BR PI0720546A BR PI0720546 A2 BRPI0720546 A2 BR PI0720546A2
Authority
BR
Brazil
Prior art keywords
compound
inhibitor
drug
pharmaceutical composition
treating cancer
Prior art date
Application number
BRPI0720546-5A
Other languages
English (en)
Inventor
Haruko Kawato
Masaki Miyazaki
Yuuichi Sugimoto
Hiroyuki Naito
Tooru Okayama
Tsunehiko Soga
Kouichi Uoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BRPI0720546A2 publication Critical patent/BRPI0720546A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0720546-5A 2006-12-14 2007-12-12 Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto BRPI0720546A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006336662 2006-12-14
PCT/JP2007/073930 WO2008072655A1 (ja) 2006-12-14 2007-12-12 イミダゾチアゾール誘導体

Publications (1)

Publication Number Publication Date
BRPI0720546A2 true BRPI0720546A2 (pt) 2015-06-23

Family

ID=39511672

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720546-5A BRPI0720546A2 (pt) 2006-12-14 2007-12-12 Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto

Country Status (11)

Country Link
US (1) US20090312310A1 (pt)
EP (1) EP2103619A4 (pt)
JP (1) JPWO2008072655A1 (pt)
KR (1) KR20090090383A (pt)
CN (1) CN101605798A (pt)
AU (1) AU2007332493A1 (pt)
BR (1) BRPI0720546A2 (pt)
CA (1) CA2672565A1 (pt)
MX (1) MX2009006397A (pt)
TW (1) TW200831518A (pt)
WO (1) WO2008072655A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009151069A1 (ja) * 2008-06-12 2009-12-17 第一三共株式会社 ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
JP2011037819A (ja) * 2008-11-21 2011-02-24 Tosoh Corp ヒドロキシアルキルトリエチレンジアミン類の製造方法
PL2380892T3 (pl) * 2009-01-16 2014-08-29 Daiichi Sankyo Co Ltd Pochodna imidazotiazolowa mająca strukturę pierścienia proliny
UA107814C2 (uk) 2009-11-12 2015-02-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи мdм2
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
JP2014500870A (ja) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
WO2012155066A2 (en) 2011-05-11 2012-11-15 Shaomeng Wang Spiro-oxindole mdm2 antagonists
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013080141A1 (en) * 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
EP3778584A1 (en) 2014-06-19 2021-02-17 ARIAD Pharmaceuticals, Inc. Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
SG11201808728QA (en) 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
US11332479B2 (en) 2016-07-05 2022-05-17 Korea Institute Of Science And Technology Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same
KR101948805B1 (ko) * 2016-07-05 2019-02-15 한국과학기술연구원 항종양 효과를 갖는 이미다조옥사졸 유도체 및 이를 포함하는 약학적 조성물
CN112912143A (zh) 2018-10-08 2021-06-04 美国密歇根州立大学试剂中心 小分子mdm2蛋白降解剂
KR20230005160A (ko) 2020-03-19 2023-01-09 카이메라 쎄라퓨틱스 인코포레이티드 Mdm2 분해제 및 이의 용도
WO2022019920A1 (en) 2020-07-24 2022-01-27 Verastem, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US11548866B1 (en) 2021-11-22 2023-01-10 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
US11504381B1 (en) * 2021-11-22 2022-11-22 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271480A (en) * 1985-04-22 1990-07-10 Toyo Jozo Co., Ltd. 5,6-dihydroimidazo[2,1-b]thiazole-2-carboxamide derivatives or salts thereof
JP3670309B2 (ja) * 1993-04-01 2005-07-13 第一製薬株式会社 二環性複素環化合物
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
IL144294A0 (en) * 1999-01-29 2002-05-23 Univ Illinois P53 inhibitors and therapeutic use of the same
US6979551B2 (en) 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
JP2002105085A (ja) * 2000-09-28 2002-04-10 Yamanouchi Pharmaceut Co Ltd 新規イミダゾチアゾール誘導体
NZ532463A (en) 2001-11-13 2007-02-23 Dimensional Pharm Inc Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
ATE397925T1 (de) 2001-12-18 2008-07-15 Hoffmann La Roche Cis-imidazoline als mdm2-hemmer
PL370823A1 (en) 2001-12-18 2005-05-30 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
US20060189511A1 (en) 2002-05-13 2006-08-24 Koblish Holly K Method for cytoprotection through mdm2 and hdm2 inhibition
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
US20040197893A1 (en) 2002-10-16 2004-10-07 Carsten Schubert HDM2-inhibitor complexes and uses thereof
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
UA82230C2 (en) 2003-04-25 2008-03-25 Орто-Макнейл Фармасьютикел, Инк. Substituted 1,4-diazepines and uses thereof
US20040213264A1 (en) 2003-04-25 2004-10-28 Nortel Networks Limited Service class and destination dominance traffic management
CN100465163C (zh) 2003-06-17 2009-03-04 霍夫曼-拉罗奇有限公司 顺式-2,4,5-三芳基-咪唑啉类化合物
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
AU2004253245B2 (en) * 2003-06-17 2010-02-11 F. Hoffmann-La Roche Ag CIS-imidazolines as MDM2 inhibitors
JP4814228B2 (ja) 2004-05-18 2011-11-16 エフ．ホフマン−ラ ロシュ アーゲー 新規ｃｉｓ−イミダゾリン
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
KR100944301B1 (ko) 2005-02-22 2010-02-24 더 리젠츠 오브 더 유니버시티 오브 미시간 Ｍｄｍ２의 소분자 억제제 및 이의 용도
CA2599476A1 (en) 2005-03-16 2006-09-21 F. Hoffmann-La Roche Ag Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments

Also Published As

Publication number Publication date
TW200831518A (en) 2008-08-01
US20090312310A1 (en) 2009-12-17
CA2672565A1 (en) 2008-06-19
CN101605798A (zh) 2009-12-16
AU2007332493A1 (en) 2008-06-19
KR20090090383A (ko) 2009-08-25
MX2009006397A (es) 2009-08-13
EP2103619A4 (en) 2011-11-23
JPWO2008072655A1 (ja) 2010-04-02
WO2008072655A1 (ja) 2008-06-19
EP2103619A1 (en) 2009-09-23

Similar Documents

Publication Publication Date Title
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0722053A2 (pt) método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina
BR112013023175A2 (pt) composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
CL2007001435A1 (es) Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer.
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0821209A2 (pt) composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
BRPI0907976A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0814777A2 (pt) Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica.
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
BRPI0720169A2 (pt) Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BRPI0815360A2 (pt) Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.